Ceftriaxone Ameliorates Motor Deficits and Protects Dopaminergic Neurons in 6-Hydroxydopamine-Lesioned Rats
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is caused by the degeneration of dopaminergic neurons in substantia nigra. There is no current promising treatment for neuroprotection of dopaminergic neurons. Ceftriaxone is a beta-lactam antibiotic and has been reported to offer neuroprotective effects (Rothstein, J.-D., Patel, S., Regan, M.-R., Haenggeli, C., Huang, Y.-H., Bergles, D.-E., Jin, L., Dykes, H.-M., Vidensky, S., Chung, D.-S., Toan, S.-V., Bruijn, L.-I., Su, Z.-Z., Gupta, P., and Fisher, P.-B. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Nature433, 73-77). In the present study, efficacy of ceftriaxone in neuroprotection of dopaminergic neurons and amelioration of motor deficits in a rat model of Parkinson's disease were investigated. Ceftriaxone was administrated in 6-hydroxydopamine-lesioned rats. Using behavioral tests, grip strength and numbers of apomorphine-induced contralateral rotation were declined in the ceftriaxone-treated group. More importantly, cell death of dopaminergic neurons was found to decrease. In addition, both the protein expression and immunoreactivity for GLT-1 were up-regulated. The present results strongly indicate that ceftriaxone is a potential agent in the treatment of Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, dyskinesia, motor impairment and memory loss were all reverted upon CTX administration [233,234,237,238,239,240,242,243,244], although conflicting evidence still remains about its ability to improve learning outcomes [245].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
Experimental — accuracy not yet measuredIn the citing paper
“As a consequence, dyskinesia, motor impairment and memory loss were all reverted upon CTX administration [233,234,237,238,239,240,242,243,244], although conflicting evidence still remains about its ability to improve learning outcomes [245].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
In the citing paper
“At the neuronal level, pre- or post- treatment with CTX prevented the loss of TH-positive neurons, reduced glutamatergic hyperactivity, and promoted neurogenesis at the level of SN and hippocampal dentate gyrus in different rat models of the disease [233,237,238,239,240,241,242].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [242]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80086-0 · Cited by 2,534
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518
Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis
Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380114 · Cited by 1,471
Perlmutter, J. S., & Mink, J. W. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112824 · Cited by 1,073
Animal models of Parkinson's disease
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002) · BioEssays · doi:10.1002/bies.10067 · Cited by 592
Brain Glutamate Transporter Proteins Form Homomultimers
Haugeto, Ø., Ullensvang, K., Levy, L. M., Chaudhry, F. A., Honoré, T., Nielsen, M., Lehre, K. P., & Danbolt, N. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27715 · Cited by 488
Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., Gearing, M., Levey, A. I., Chin, L.-S., & Li, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509079200 · Cited by 483
Requena, J. R., Chao, C.-C., Levine, R. L., & Stadtman, E. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.69 · Cited by 415
Actions of TNF‐α on glutamatergic synaptic transmission in the central nervous system
Pickering, M., Cumiskey, D., & O'Connor, J. J. (2005) · Experimental Physiology · doi:10.1113/expphysiol.2005.030734 · Cited by 411
Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity
Smith, Y., & Parent, A. (1988) · Brain Research · doi:10.1016/0006-8993(88)90177-1 · Cited by 331
The Genetics of Parkinson Disease
Bekris, L. M., Mata, I. F., & Zabetian, C. P. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383572 · Cited by 301
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., Kennedy, R. T., & Rebec, G. V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.004 · Cited by 280
A Neuronal Glutamate Transporter Contributes to Neurotransmitter GABA Synthesis and Epilepsy
Sepkuty, J. P., Cohen, A. S., Eccles, C., Rafiq, A., Behar, K., Ganel, R., Coulter, D. A., & Rothstein, J. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06372.2002 · Cited by 264
Nakanishi, H., Kita, H., & Kitai, S. T. (1987) · Brain Research · doi:10.1016/0006-8993(87)91525-3 · Cited by 243
Kanai, Y., & Hediger, M. A. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.073 · Cited by 213
Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation
Chu, K., Lee, S.-T., Sinn, D.-I., Ko, S.-Y., Kim, E.-H., Kim, J.-M., Kim, S.-J., Park, D.-K., Jung, K.-H., Song, E.-C., et al. (2007) · Stroke · doi:10.1161/01.str.0000252091.36912.65 · Cited by 188
Lewerenz, J., Albrecht, P., Tien, M. T., Henke, N., Karumbayaram, S., Kornblum, H. I., Wiedau‐Pazos, M., Schubert, D., Maher, P., & Methner, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06347.x · Cited by 175
Neuroprotective potential of ceftriaxone in in vitro models of stroke
Lipski, J., Wan, C. K., Bai, J., Pi, R., Li, D., & Donnelly, D. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.003 · Cited by 170
Figiel, M., & Engele, J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03596.2000 · Cited by 170
Ceftriaxone: An Update of its Use in the Management of Community-Acquired and Nosocomial Infections
Lamb, H. M., Ormrod, D. J., Scott, L. J., & Figgitt, D. P. (2002) · Drugs · doi:10.2165/00003495-200262070-00005 · Cited by 153
Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges
Nau, R., Prange, H. W., Muth, P., Mahr, G., Menck, S., Kolenda, H., & Sörgel, F. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1518 · Cited by 141
Plaitakis, A., & Shashidharan, P. (2000) · Journal of Neurology · doi:10.1007/pl00007757 · Cited by 135
Verma, R., Mishra, V., Sasmal, D., & Raghubir, R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.04.021 · Cited by 128
Meredith, G. E., Totterdell, S., Beales, M., & Meshul, C. K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.06.005 · Cited by 128
Scott, H. L., Pow, D. V., Tannenberg, A. E. G., & Dodd, P. R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-j0004.2002 · Cited by 127
The Copper Chaperone CCS Is Abundant in Neurons and Astrocytes in Human and Rodent Brain
Rothstein, J. D., Dykes‐Hoberg, M., Corson, L. B., Becker, M., Cleveland, D. W., Price, D. L., Culotta, V. C., & Wong, P. C. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720422.x · Cited by 125
Dorner, J. L., Miller, B., Barton, S. J., Brock, T. J., & Rebec, G. V. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.12.004 · Cited by 112
Rao, V. L. R., Bowen, K. K., & Dempsey, R. J. (2001) · Neurochemical Research · doi:10.1023/a:1010956711295 · Cited by 109
Chung, E. K. Y., Chen, L. W., Chan, Y. S., & Yung, K. K. L. (2008) · Journal of Comparative Neurology · doi:10.1002/cne.21852 · Cited by 105
Self-citationTikka, T., Usenius, T., Tenhunen, M., Keinänen, R., & Koistinaho, J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00543.x · Cited by 96
Sari, Y., Prieto, A. L., Barton, S. J., Miller, B. R., & Rebec, G. V. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-62 · Cited by 84
Deep Brain Stimulation Does Not Silence Neurons in Subthalamic Nucleus in Parkinson's Patients
Carlson, J. D., Cleary, D. R., Cetas, J. S., Heinricher, M. M., & Burchiel, K. J. (2010) · Journal of Neurophysiology · doi:10.1152/jn.00363.2009 · Cited by 81
Hazell, A. S., Itzhak, Y., Liu, H., & Norenberg, M. D. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052216.x · Cited by 80
Hota, S. K., Barhwal, K. K., Ray, K., Singh, S. B., & Ilavazhagan, G. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.01.003 · Cited by 74
McIntyre, C. C., & Thakor, N. V. (2002) · Critical Reviews? in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v30.i456.20 · Cited by 60
Clinical Trials for Neuroprotection in ALS
Siciliano, G., Carlesi, C., Pasquali, L., Piazza, S., Pietracupa, S., Fornai, F., Ruggieri, S., & Murri, L. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791292648 · Cited by 48
Demel, C., Hoegen, T., Giese, A., Angele, B., Pfister, H.-W., Koedel, U., & Klein, M. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-7 · Cited by 32
Intrastriatal injection of dl-α-aminoadipate reduces kainate toxicity in vitro
McBean, G. J. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90316-v · Cited by 30
Huang, S., He, J., Zhao, D.-M., Xu, X., Tan, H., & Li, H. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-010-9543-7 · Cited by 22
Research works printed but not linked: 2
- Paxinos G., and Watson C.. (1986)The Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, San Diego. [Google Scholar]
- Mandell G. L., and Sande M. A. (1990) Antimicrobial agents. In Goodman and Gilman’s The Pharmacological Basic of Therapeutics (Gilman A. G., Rall T. W., Niles A. S., and Taylor P., Eds.), pp 1085–1092, Pergamon Press, New York. [Google Scholar]
Cited by
Takahashi, K., Foster, J. B., & Lin, C.-L. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1937-8 · Cited by 208
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
Current approaches to enhance glutamate transporter function and expression
Fontana, A. C. K. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13200 · Cited by 168
Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123
Metadata
- Authors
- Leung, T. C. H., Lui, C. N. P., Chen, L. W., Yung, W. H., Chan, Y. S., & Yung, K. K. L.
- Affiliations
- Hong Kong Baptist University (HK)
- Air Force Medical University (CN)
- Chinese University of Hong Kong (HK)
- University of Hong Kong (HK)
- Corresponding author
- Yung, K. K. L.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-11-04
- Volume
- 3
- Issue
- 1
- Pages
- 22-30
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC3369786
- OpenAlex
- W2024142654
- Cited by
- 78
- References
- 40
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 6 · 2019: 9 · 2018: 6 · 2017: 11 · 2016: 6 · 2015: 5 · 2014: 7 · 2013: 4
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HKBU Institutional Repository (Hong Kong Baptist University) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ceftriaxone, Parkinson's disease, neuroprotection, dopaminergic neurons, substantia nigra, 6-hydroxydopamine lesion, motor impairment, GLT-1, glutamate transporters, beta-lactam antibiotics, cell death
- MeSH terms
- Animals, Behavior, Animal, Brain, Ceftriaxone, Female, Motor Activity, Blotting, Western, Oxidopamine, Rats, Sprague-Dawley, Neuroprotective Agents, Parkinsonian Disorders, Rats, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.